400 Capitol Street, NW
Washington, DC 20001
- Toll Free 1.888.564.6273
- Local 202.783.3870
Click here to download the full, .pdf version which includes pictrues!
A recent report from the non-partisan Tax Foundation shows who will bear the funding burden for the federal government’s health care take over, and proves it’s never too early to say “I told you so.” Nine of the top ten states that will pay the highest income taxes under a “surtax” plan currently being considered in the Democrat-dominated House of Representatives went for Barack Obama last fall. By an average of 25 percent.
One of the big points we hear from the grassroots again and again is "If this public plan is so good, will Congress enroll?" The answer is, of course not. That's the give-away. The new public option will be good enough for everyone else, but our elected officials will keep their own cushy plan.
While the larger debate over liberals' proposed hostile government takeover of America's medical system continues to rage, an opportunity was recently missed to inject some competition in one important area: the life-saving biologic drug market.The Senate HELP committee passed legislation last week that would prevent generic companies from entering the market to compete with brand providers. These "biogenerics" would provide downward pressure on prices for drugs like Insulin and Avastin (a colon cancer medicine), but not if Congress continues to allow roadblocks to competition.
The Wall Street Journal reports this morning that the European Union and the United States have again chosen different paths regarding free trade, this time with South Korea. However, for once it’s old Europe that wants to boost economic output by lowering barriers. Meanwhile, in the formerly free market U.S., a Congress beholden to Big Labor throws up roadblocks.
You have to hand it to Jared Polis: For a freshman Congressman to be quoted in the the NY Times and the Wall Street Journal within 24 hours (and not for some misdeed) is an achievement.
July 16, 2009Members of the 111th CongressU.S. House of RepresentativesWashington, D.C. 20515Dear Representative,FreedomWorks, a grassroots organization with more than 750,000 members nationwide, is actively engaged in the current debate over health care reform and has been a strong advocate of market-based reforms that would expand consumer choice and competition in the health care sector. Independent of the larger debate over the direction of health care reform in America, however, I would like to alert you to a potentially dangerous amendment that is being offered to H.R. 3200, American’s Health Choices Act of 2009 by Rep. Eshoo that would severely restrict the emerging market for biogeneric drugs.With the rising cost of pharmaceutical drugs and healthcare, it is increasingly important to encourage competition in the market for life saving therapies. Biologics show great promise and have been used to produce insulin, human growth hormone, and other important therapies. Globally, the market for these drugs has increased to more than $60 billion. To expand this market and increase access to these life-saving drugs, it is important that the Food and Drug Administration has a regulatory pathway to approve biogenerics, or biologic follow-ons. Much like generics, biogenerics hold the promise of new competiton and expanded consumer choice in new therapies to treat a variety of conditions, from AIDS to Alzheimer’s, to several different cancers.Currently, the FDA has limited authority to approve biogenerics. Many pharmaceutical companies claim that biologics are too complex to be produced as generics. This is not true; there are a number of pharmaceutical companies—brand name and generic—that have the capability and desire to enter the market for biologics with expiring patents. One biogeneric has already been approved by the FDA, and the agency has stated that it believes it is possible to establish an abbreviated approval process for these drugs that allows manufacturers to establish their bioequivalence. Already, the European Union and Australia have established procedures to approve biogenerics. As an important component of health care reform, Congress should move forward with legislation to ensure all Americans enjoy access to the latest therapeutic drugs at the most affordable prices. Unfortunately, the Eshoo Amendment includes a 12-year exclusivity period that will do little to promote the competition necessary to expand consumer choice and check rising health care costs. A market approach is the correct solution to getting less expensive therapies to patients, as it also encourages the development of new and desperately needed medicines. For these reasons, I urge you to vote “no” on the Eshoo Amendment. FreedomWorks will continue to follow the health care reform debate closely, advocating market-based reforms that expand patient choice and improve access to life-saving therapies.Sincerely,Matt KibbePresident and CEO
Remember when Massachusetts overhauled its health care system?It wasn't too long ago. Two thousand and six (AD) to be precise.Well, the utopian project is now forcing its passengers to brace for impact as it experiences potentially terminal turbulence due to out of control costs associated with the massive entitlement program.
Christina Romer, chair of the President’s Council of Economic Advisors, recently admitted in an interview with CNBC’s Maria Bartiromo that it is effectively impossible to accurately measure how many jobs the stimulus saved, will save, created, or will create.
Word on the street is that this flow chart vastly understates the complexity of the House Democrats' healthcare plan.May Gaia save us all.Update (roughly 45 minutes after original post): The original post has not been altered. If one briefly examines the image, one would learn that the source of it is:Joint Economic Committee, Republican Staff. (continued below in response to Sickle.)